logo
Plus   Neg
Share
Email

Roche's Tecentriq Gets 2 EU Approvals To Treat Adults With NSCLC, ES-SCLC

Swiss drug major Roche Group (RHHBY) announced Friday two approvals from European Commission for Tecentriq (atezolizumab) to treat adults with non-squamous non-small cell lung cancer or NSCLC, the most common form of advanced lung cancer, and extensive-stage small cell lung cancer or ES-SCLC, respectively.

In a statement, the company announced that the European Commission or EU has approved and granted marketing authorisation for Tecentriq in combination with chemotherapy (carboplatin and Abraxane), for the initial treatment of adults with metastatic non-squamous NSCLC who do not have EGFR mutant or ALK-positive NSCLC.

This approval is based on results from the Phase III IMpower130 study, which demonstrated that the Tecentriq combination therapy helped people live significantly longer, compared with chemotherapy alone in the intention-to-treat wild-type or ITT-WT population. The Tecentriq-based combination also significantly reduced the risk of disease worsening or death compared with chemotherapy alone.

Separately, EU approved Tecentriq in combination with chemotherapy for the initial treatment of people with extensive-stage small cell lung cancer or ES-SCLC. Roche noted that this combination is the first and only cancer immunotherapy approved by the European Medicines Agency for the initial treatment of ES-SCLC. The combination significantly improved overall survival and progression-free survival for the first time in over 20 years.

This approval is based on results from the Phase III IMpower133 study, which showed that Tecentriq in combination with chemotherapy helped people live significantly longer compared with chemotherapy alone in the intention-to-treat or ITT population. The Tecentriq-based combination also significantly reduced the risk of disease worsening or death compared with chemotherapy alone.

At present, Roche has nine Phase III lung cancer studies underway evaluating Tecentriq alone or in combination with other medicines across different types of lung cancer.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Swiss food giant Nestle SA said it is committed to achieving zero net greenhouse gas emissions by 2050, noting that climate change is one of the biggest threats faced by the world. As part of its efforts to achieve the goal, Nestle said it will launch more plant-based food and beverage options that are more environment friendly. Coffee giant Starbucks Corp. is set to open the world's largest Starbucks Reserve Roastery on November 15 on Chicago's Magnificent Mile. It will open in an interactive four-storey glass-clad building in 43,000 square feet space, employing about 200 people. The site at the corner of North Michigan Avenue and Erie Street was previously occupied by Crate & Barrel. United Parcel Service Inc. agreed to pay $8.4 million to the United States to settle allegations that it overcharged federal agencies for package delivery services, the U.S. Justice Department said. Under a General Services Administration or GSA contract, UPS was required to provide GSA with certain lower prices for its services.
Follow RTT